Levomilnacipran in the treatment of major depressive disorder : An analysis of efficacy and safety data from two phase III studies

被引：0
|
作者：
Greenberg, W. [1 ]
Commoll, C. [1 ]
Bose, A. [1 ]
Li, H. [1 ]
Ruth, A. [2 ]
Hussainzada, N. [3 ]
机构：
[1] Forest Res Inst, Jersey City, NJ USA
[2] Prescott Med, Commun Grp, Chicago, IL USA
[3] Forest Labs Inc, Washington, DC USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-14-014
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of sertraline in the treatment of pediatric major depressive disorder (MDD)
    Wagner, K
    Donnelly, C
    Wohlberg, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S231 - S232
  • [32] Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
    Wesnes, Keith A.
    Gommoll, Carl
    Chen, Changzheng
    Sambunaris, Angelo
    McIntyre, Roger S.
    Harvey, Philip D.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2017, 32 (02) : 72 - 79
  • [33] COMPARATIVE ANALYSIS OF THE EFFICACY AND SAFETY OF ESCITALOPRAM WITH SERTRALINE AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
    Walczak, J.
    Malysiak, S.
    Rowinska, M.
    VALUE IN HEALTH, 2010, 13 (03) : A107 - A107
  • [34] Efficacy and Safety of Vilazodone treatment for Major Depressive Disorder (MDD): A Pooled analysis of 3390 patients
    Gbreel, Mohamed Ibrahim
    Al-Kafarna, Mohammed
    Almaghary, Bashar Khaled
    Sabra, Hamdy Khaled
    Adwan, Mustafa
    Abdelgawad, Osama Khalid
    Elsheikh, Fatma
    Abdullah, Ahmed Mahmoud
    Almadhoon, Hossam Waleed
    Amer, Esraa Abdelhameid
    Elsnhory, Ahmed
    NEUROLOGY, 2023, 100 (17)
  • [35] Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder
    Palmer, Emma C.
    Binns, Lindsey N.
    Carey, Heather
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (08) : 1030 - 1039
  • [36] Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder
    Hansen, RA
    Gartlehner, G
    Lohr, KN
    Gaynes, BN
    Carey, TS
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 415 - 426
  • [37] The efficacy of vortioxetine for the treatment of major depressive disorder
    Dhir, Ashish
    Sarvaiya, Jayrajsinh
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (12) : 1349 - 1363
  • [38] The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis
    Meeker A.S.
    Herink M.C.
    Haxby D.G.
    Hartung D.M.
    Systematic Reviews, 4 (1)
  • [39] Efficacy and Safety of Escitalopram in the Treatment of Major Depressive Disorder in Chinese Patients: A Meta-Analysis Study
    Gou, Mingyang
    2019 ASIA-PACIFIC CONFERENCE ON CLINICAL MEDICINE AND PUBLIC HEALTH (CMPH 2019), 2019, : 83 - 88
  • [40] The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker, Amanda
    Hartung, Daniel
    Herink, Megan
    Haxby, Dean
    PHARMACOTHERAPY, 2014, 34 (10): : E262 - E262
12345